Trial Condition(s):

Hyperphosphatemia, Dialysis

Long-term treatment on BAY77-1931 (lanthanum carbonate) to measure lanthanum concentrations in bone

Bayer Identifier:

11810

ClinicalTrials.gov Identifier:

NCT00767637

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis

Inclusion Criteria
- Patients undergoing dialysis or plan to start dialysis before the initial administration of the study medication
Exclusion Criteria
- Patients with severe hypocalcemia (adjusted serum calcium level of <7.5 mg/dL)

Trial Summary

Enrollment Goal
14
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Fosrenol (Lanthanum Carbonate, BAY77-1931)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Sanin Rosai Hospital

Yonago, Japan, 683-0002

Status
Completed
 
Locations

Seseragi Hospital

Isesaki, Japan, 379-2211

Status
Completed
 

Trial Design